Article Summary
王卫东1 白峰2△ 刘建3 张金康3 赵一南3.不同剂量rhBMP-2/CPC 体内骨诱导活性的比较研究*[J].现代生物医学进展英文版,2012,12(27):5209-5213.
不同剂量rhBMP-2/CPC 体内骨诱导活性的比较研究*
Effects of Porpous CPC with Different Concentrations of rhBMP -2 onInductive Osteogenesis in Vivo*
  
DOI:
中文关键词: 磷酸钙骨水泥  重组人骨形态发生蛋白-2  诱导成骨
英文关键词: Calcium phosphate cemen  Recombinant human bone morphogenetic protein-2  Inductive osteogenesis
基金项目:国家十一五科技支撑计划(2006BAI16B02)
Author NameAffiliation
WANG Wei-dong1, BAI Feng2△, LIU Jian3, ZHANG Jin-kang3, ZHAO Yi-nan3 西宁市第二人民医院骨科 
Hits: 974
Download times: 1402
中文摘要:
      目的:对比不同剂量rhBMP-2 与多孔CPC 复合后的诱导成骨效应,探讨与多孔CPC 复合后的rhBMP-2 的量效关系。方法: 将0.5 mg/ml、1 mg/ml、2 mg/ml、3 mg/ml 4 种不同剂量的rhBMP-2 与多孔CPC 材料复合后,植入36 只小鼠双侧股部肌肉内,分别 于术后1 周、2 周及4 周取材,通过大体观察、组织学分析、形态计量学分析、荧光双标测定,观察4 组诱导成骨情况。结果:植入1 周,rhBMP-2 与多孔CPC 材料复合表现出了较明显的剂量依赖性,含有较多rhBMP-2 的材料内诱导形成的骨组织也较多,但骨 组织的增加并未随着rhBMP-2 剂量的增加而连续递增,2 mg 组和3 mg 组新生骨组织含量无明显差异(P>0.05)。植入4 周,新生 骨组织向材料内部生长,但此时的新生骨组织面积较2 周增加不显著(P>0.05)。0.5 mg 组新生骨组织含量仍处于最低水平,而其 它三组之间却无明显差异(P>0.05)。结论:在0.5 mg/ml-2.0 mg/ml 剂量范围,与多孔CPC 复合的rhBMP-2 诱导成骨量与其剂量 成正比,最佳剂量为2 mg/ml。
英文摘要:
      Objective: To investigate the biological effect of inductive osteogenesis of porous CPC with different dose of rhBMP-2 and the interrelation to the dose of rhBMP-2. Methods: The porous CPC with 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 3 mg/ml rhBMP-2 were respectively implanted into the muscle of 36 mice. The mice were killed at 1, 2 and 4 weeks postoperation. The biological effect of inductive osteogenesis was observed by histology, morphometry and fluorescence. Results: At 1 week, the dose dependent of rhBMP-2 could be observed obviously. The better ossification was observed in the porous CPC with more rhBMP-2. But the newly formed bone did not increase continously with the increase of rhBMP-2. There were no significant difference in newly formed bone between 2 mg/ml group and 3mg/ml group (P>0.05). At 4 weeks, newly formed bone had grown into the porous CPC. But there were no significant difference in the area of newly formed bone at 4 weeks compared with that at 2 weeks (P>0.05). The content of new bone in 0.5 mg/ml group was significantly lower than that in other groups. There were no obvious differences in content of new bone among 1 mg/l, 2 mg/l and 3mg/ml groups (P>0.05). Conclusions: The content of new bone increases with the increasing in the dose of rhBMP-2 in the dose cope of 0.5mg/ml-2.0mg/ml, and the optimal dose of rhBMP-2 is 2.0mg/ml.
View Full Text   View/Add Comment  Download reader
Close